127 related articles for article (PubMed ID: 38858522)
1. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).
Zeng L; Perin J; Gross AL; Shade D; Lanctôt KL; Lerner AJ; Mintzer JE; Brawman-Mintzer O; Padala PR; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Herrmann N; Rosenberg PB
Int J Geriatr Psychiatry; 2024 Jun; 39(6):e6108. PubMed ID: 38858522
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.
Rosenberg PB; Lanctôt KL; Drye LT; Herrmann N; Scherer RW; Bachman DL; Mintzer JE; ADMET Investigators
J Clin Psychiatry; 2013 Aug; 74(8):810-6. PubMed ID: 24021498
[TBL] [Abstract][Full Text] [Related]
3. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial.
Lanctôt KL; Chau SA; Herrmann N; Drye LT; Rosenberg PB; Scherer RW; Black SE; Vaidya V; Bachman DL; Mintzer JE
Int Psychogeriatr; 2014 Feb; 26(2):239-46. PubMed ID: 24169147
[TBL] [Abstract][Full Text] [Related]
4. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.
Scherer RW; Drye L; Mintzer J; Lanctôt K; Rosenberg P; Herrmann N; Padala P; Brawman-Mintzer O; Burke W; Craft S; Lerner AJ; Levey A; Porsteinsson A; van Dyck CH;
Trials; 2018 Jan; 19(1):46. PubMed ID: 29347996
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions for apathy in Alzheimer's disease.
Ruthirakuhan MT; Herrmann N; Abraham EH; Chan S; Lanctôt KL
Cochrane Database Syst Rev; 2018 May; 5(5):CD012197. PubMed ID: 29727467
[TBL] [Abstract][Full Text] [Related]
6. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Mintzer J; Lanctôt KL; Scherer RW; Rosenberg PB; Herrmann N; van Dyck CH; Padala PR; Brawman-Mintzer O; Porsteinsson AP; Lerner AJ; Craft S; Levey AI; Burke W; Perin J; Shade D;
JAMA Neurol; 2021 Nov; 78(11):1324-1332. PubMed ID: 34570180
[TBL] [Abstract][Full Text] [Related]
7. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.
Herrmann N; Rothenburg LS; Black SE; Ryan M; Liu BA; Busto UE; Lanctôt KL
J Clin Psychopharmacol; 2008 Jun; 28(3):296-301. PubMed ID: 18480686
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease.
Andrade C
J Clin Psychiatry; 2022 Feb; 83(1):. PubMed ID: 35120284
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
Padala PR; Padala KP; Lensing SY; Ramirez D; Monga V; Bopp MM; Roberson PK; Dennis RA; Petty F; Sullivan DH; Burke WJ
Am J Psychiatry; 2018 Feb; 175(2):159-168. PubMed ID: 28945120
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Psychostimulants for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Iwata N
Pharmacopsychiatry; 2020 Apr; 53(3):109-114. PubMed ID: 32000270
[TBL] [Abstract][Full Text] [Related]
12. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of methylphenidate in preschool children with ADHD.
Wigal T; Greenhill L; Chuang S; McGOUGH J; Vitiello B; Skrobala A; Swanson J; Wigal S; Abikoff H; Kollins S; McCRACKEN J; Riddle M; Posner K; Ghuman J; Davies M; Thorp B; Stehli A
J Am Acad Child Adolesc Psychiatry; 2006 Nov; 45(11):1294-1303. PubMed ID: 17028508
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356
[No Abstract] [Full Text] [Related]
16. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
[No Abstract] [Full Text] [Related]
17. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
Huss M; Ginsberg Y; Tvedten T; Arngrim T; Philipsen A; Carter K; Chen CW; Kumar V
Adv Ther; 2014 Jan; 31(1):44-65. PubMed ID: 24371021
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
[TBL] [Abstract][Full Text] [Related]
19. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
Lanctôt KL; Chen C; Mah E; Kiss A; Li A; Shade D; Scherer RW; Vieira D; Coulibaly H; Rosenberg PB; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Burke WJ; Mintzer J; Herrmann N
Int Psychogeriatr; 2023 Nov; 35(11):664-672. PubMed ID: 37066690
[TBL] [Abstract][Full Text] [Related]
20. Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial.
Maier F; Spottke A; Bach JP; Bartels C; Buerger K; Dodel R; Fellgiebel A; Fliessbach K; Frölich L; Hausner L; Hellmich M; Klöppel S; Klostermann A; Kornhuber J; Laske C; Peters O; Priller J; Richter-Schmidinger T; Schneider A; Shah-Hosseini K; Teipel S; von Arnim CAF; Wiltfang J; Jessen F
JAMA Netw Open; 2020 May; 3(5):e206027. PubMed ID: 32463470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
